International Journal of Drug Policy

Papers
(The H4-Index of International Journal of Drug Policy is 40. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 500 papers]. The publications cover those that have been published in the past four years, i.e., from 2019-08-01 to 2023-08-01.)
ArticleCitations
The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis326
Prevalence and forms of cannabis use in legal vs. illegal recreational cannabis markets101
Tackling the overdose crisis: The role of safe supply93
An assessment of the limits of detection, sensitivity and specificity of three devices for public health-based drug checking of fentanyl in street-acquired samples92
“Everything is not right anymore”: Buprenorphine experiences in an era of illicit fentanyl76
Fentanyl shock: The changing geography of overdose in the United States74
Evaluating the impacts of cannabis legalization: The International Cannabis Policy Study71
Safer opioid distribution in response to the COVID-19 pandemic68
Losing the uphill battle? Emergent harm reduction interventions and barriers during the opioid overdose crisis in Canada67
Kratom policy: The challenge of balancing therapeutic potential with public safety67
Changes in substance supply and use characteristics among people who use drugs (PWUD) during the COVID-19 global pandemic: A national qualitative assessment in Canada65
COVID-19 and the health of people who use drugs: What is and what could be?61
Syringe services program (SSP) operational changes during the COVID-19 global outbreak60
Policing space in the overdose crisis: A rapid ethnographic study of the impact of law enforcement practices on the effectiveness of overdose prevention sites59
Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?56
Buprenorphine dispensing in an epicenter of the U.S. opioid epidemic: A case study of the rural risk environment in Appalachian Kentucky53
The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis52
Opioid-related deaths in Europe: Strategies for a comprehensive approach to address a major public health concern51
Associations between perceived illicit fentanyl use and infectious disease risks among people who inject drugs51
Ambiguous identities of drugs and people: A scoping review of opioid-related stigma49
Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update48
The impact of COVID-19 restrictions on needle and syringe programme provision and coverage in England48
Continuing increased access to buprenorphine in the United States via telemedicine after COVID-1948
“We don’t got that kind of time, man. We’re trying to get high!”: Exploring potential use of drug checking technologies among structurally vulnerable people who use drugs47
A Scoping Review of Barriers and Facilitators to Implementation of Medications for Treatment of Opioid Use Disorder within the Criminal Justice System47
Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston47
Communicating THC levels and ‘dose’ to consumers: Implications for product labelling and packaging of cannabis products in regulated markets45
Integrated models of care for people who inject drugs and live with hepatitis C virus: A systematic review44
An outbreak of novel psychoactive substance benzodiazepines in the unregulated drug supply: Preliminary results from a community drug checking program using point-of-care and confirmatory methods44
COVID-19 - Enacting a ‘new normal’ for people who use drugs44
“They're making it so hard for people to get help:” Motivations for non-prescribed buprenorphine use in a time of treatment expansion43
Prescription drug monitoring programs operational characteristics and fatal heroin poisoning43
“Someone who is in this thing that I am suffering from”: The role of peers and other facilitators for task sharing substance use treatment in South African HIV care42
“You are not clean until you're not on anything”: Perceptions of medication-assisted treatment in rural Appalachia41
‘It's too much, I'm getting really tired of it’: Overdose response and structural vulnerabilities among harm reduction workers in community settings41
The value of unsolicited online data in drug policy research41
Syringe services programs: An examination of legal, policy, and funding barriers in the midst of the evolving opioid crisis in the U.S.41
Care during COVID-19: Drug use, harm reduction, and intimacy during a global pandemic41
Comparing Canadian and United States opioid agonist therapy policies41
Access to cannabidiol without a prescription: A cross-country comparison and analysis40
0.0278000831604